News
- Author:
- Bruce Jancin
Publish date: April 12, 2021
The week-24 PASI 75 rate was 95% in a phase 2 study.
News
- Author:
- Bruce Jancin
Publish date: April 9, 2021
Expert says success with collagenase clostridium histolyticum–aaes injections will be all about managing expectations.
News
- Author:
- Bruce Jancin
Publish date: April 7, 2021
VEXAS is a novel adult-onset autoinflammatory syndrome in older men and is often associated with hematologic abno...
News
- Author:
- Bruce Jancin
Publish date: April 6, 2021
The response to bimekizumab was notably fast.
News
- Author:
- Bruce Jancin
Publish date: April 6, 2021
The goal of step-down therapy is lifelong tolerability.
News
- Author:
- Bruce Jancin
Publish date: April 2, 2021
Two or more cups daily slashes risk of hepatic cirrhosis and hepatocellular carcinoma.
News
- Author:
- Bruce Jancin
Publish date: April 1, 2021
“I think this will be a really helpful addition, the equivalent of a second endoscopist raising a yellow flag to take a closer look at a particular...
News
- Author:
- Bruce Jancin
Publish date: March 31, 2021
Some patients achieve functional cure after treatment withdrawal, while others face flares or other challenges.
News
- Author:
- Bruce Jancin
Publish date: March 31, 2021
“Always aim for clear skin.”
News
- Author:
- Bruce Jancin
Publish date: March 31, 2021
The rationale is to optimize the antibody response to the killed-adenovirus COVID-19 vaccine.
News
- Author:
- Bruce Jancin
Publish date: March 31, 2021
“I think this will be a really helpful addition, the equivalent of a second endoscopist raising a yellow flag to take a closer look at a particular...
News
- Author:
- Bruce Jancin
Publish date: March 29, 2021
Signal of possible gender disparity in PsA response to biologics sparks questions.
News
- Author:
- Bruce Jancin
Publish date: March 26, 2021
Results of year-long PSO-LONG trial show superior efficacy, compared with conventional reactive management.
News
- Author:
- Bruce Jancin
Publish date: March 25, 2021
Clinically meaningful hair regrowth occurred in the BRAVE-AA1 trial despite 16-year disease duration.
News
- Author:
- Bruce Jancin
Publish date: March 23, 2021
Topical JAK inhibitor displayed dual mechanisms of benefit in pivotal trials.
